Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

ConditionsAutoimmune Lymphoproliferative Syndrome Autoimmune Cytopenia Autoimmune Diseases Autoimmune Anemia Autoimmune Thrombocytopenia Autoimmune Hepatitis Autoimmune Diabetes Autoimmune Rheumatologic Disease Systemic Lupus Erythematosus Juvenile Idiopathic Arthritis Hemophagocytic Lymphohistiocytoses EBV Lymphoproliferation RAS-Associated Autoimmune Leucoproliferative Disease Primary Immunodeficiency APECED IPEX BENTA Enteropathy, Autoimmune Combined Immunodeficiency IBD

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age1-18

SponsorInstitut National de la Santé Et de la Recherche Médicale, France

About this trial

The main objective of this study is to generate diagnosis and therapeutic-decision tools through the identification of molecular causes of PIDs with autoimmunity/inflammation and the variability in disease outcome at the transcriptional level using a combination of omics signatures (transcriptomics, epigenomics, proteomics, metagenomics, metabolomics and lipidomics).

Eligibility criteria

Qualifiers

Individuals aged<18 y/o.

Individuals > 6 kg

Individuals not affected by an immune-related disease or not affected by cancer

Individuals whose parents have signed an enlightened consent.

Disqualifiers

Intake of antibiotics within 2 weeks prior inclusion

Absence of parent's or child consent form

Cytotoxic cancer treatments

antiviral treatments (HIV, hepatitis …)

Trial design

Treatments tested in this trial

Collection of samples

Treatment groups

500 Participants

are divided into 3 treatment groups

Sponsors and collaborators

Institut National de la Santé Et de la Recherche Médicale, France

Lead sponsor

Source ClinicalTrials.gov